Xin Lang Zheng Quan·2025-09-26 01:47Company Overview - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was established on May 31, 1995, and listed on August 7, 1998. The company is primarily engaged in drug manufacturing and research, covering medical devices, medical diagnostics, medical services, and pharmaceutical distribution and retail [1]. Financial Performance - For the first half of 2025, Fosun Pharma reported operating revenue of 19.514 billion yuan, a year-on-year decrease of 4.63%. However, the net profit attributable to shareholders increased by 38.96% to 1.702 billion yuan [2]. - The company has cumulatively distributed 12.593 billion yuan in dividends since its A-share listing, with 2.691 billion yuan distributed over the past three years [3]. Stock Performance - As of September 26, Fosun Pharma's stock price was 29.69 yuan per share, with a market capitalization of 79.285 billion yuan. The stock has increased by 21.02% year-to-date but has seen a decline of 4.01% over the past five trading days [1]. - The stock's trading volume on September 26 was 182 million yuan, with a turnover rate of 0.29% [1]. Shareholder Structure - As of June 30, 2025, Fosun Pharma had 230,000 shareholders, a decrease of 4.37% from the previous period. The average circulating shares per shareholder remained at 0 [2]. - The top circulating shareholder is Hong Kong Central Clearing Limited, holding 75.881 million shares, an increase of 11.194 million shares from the previous period [3].